E.E. Geduld’s Iovance Biotherapeutics IOVA Stock Holding History

E.E. Geduld’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-15,000	Closed	-$123K	–	193
2016 Q3	$123K	Buy	15,000 +5,000	+50%	+$42.3K	0.12%	120
2016 Q2	$81K	Buy	+10,000	New	+$62.8K	0.11%	113
2016 Q1	–	Sell	-20,000	Closed	-$154K	–	188
2015 Q4	$154K	Buy	20,000 +5,000	+33%	+$34.7K	0.1%	99
2015 Q3	$86K	Sell	15,000 -45,000	-75%	-$350K	0.08%	134
2015 Q2	$550K	Buy	60,000 +25,000	+71%	+$279K	0.34%	57
2015 Q1	$424K	Buy	+35,000	New	+$394K	0.28%	85

Other funds holding IOVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

E.E. Geduld's IOVA Position: Q4 2016 in Review

E.E. Geduld sold out of Iovance Biotherapeutics (IOVA) in Q4 2016, closing a stake of 15,000 shares — an estimated $123K sold.

E.E. Geduld first reported a position in IOVA in Q1 2015 and held it in 6 quarters. The position peaked at $550K in Q2 2015. 87 funds tracked by Wall St. Rank hold IOVA as of Q4 2016.

E.E. Geduld reported no remaining Iovance Biotherapeutics position as of Q4 2016 after selling out during the quarter.
E.E. Geduld sold 15,000 Iovance Biotherapeutics shares in Q4 2016, an estimated $123K.
E.E. Geduld first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 6 quarters.
E.E. Geduld's Iovance Biotherapeutics position peaked at $550K in Q2 2015.
87 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2016.

Based on E.E. Geduld's 13F filing for Q4 2016, filed 8 Feb 2017.